Gsk Share Discussion Threads

[alphorn] 09/10/2022 09:53

TM - To add to your post about late stage trials it should be noted that they can be used to increase potential patient exposure for later marketing (Phase IIIb trials) and Phase IV trials to explore more indications......... etc.

[tradermichael] 09/10/2022 09:04

The third phase of clinical trials typically lasts between one and four years. FDA Approval: Once Phase 3 has concluded, the company studying the drug can submit a New Drug Application (NDA) or a biologics license application (BLA) for the treatment to the Food and Drug Administration (FDA).

Finally, on Phase 4, after a product receives FDA approval and is on the market for consumers to use, further clinical trials may continue to gather more information on side effects, risks, benefits, and best uses. These studies are known as post-marketing surveillance (PMS) trials.

Phase 4 trials usually include hundreds to a few thousand participants.

[netcurtains] 08/10/2022 19:06

How many phases are normally after phase 3?
And how long has average phase 3 take?

Cheers Net.

[alphorn] 08/10/2022 18:33

'safety and tolerability profile' I would hope so - but does it work? That is the question.

[tradermichael] 08/10/2022 18:11

This is all you need to know:

GSK PLC on Wednesday said its drug for metastatic non-squamous non-small cell lung cancer Jemperli, or dostarlimab, is advancing to a phase 3 trial following positive results.

Jemperli is an antibody approved for the treatment of endometrial cancer in the US and EU.

Non-squamous means flat cells do not look like a fish scale under a microscope.

Citing its phase 2 Perla study, the Brentford, west London-based pharmaceuticals firm said that the safety and tolerability profile of dostarlimab was consistent with previous clinical trials of similar regimens.

Further, in its Costar phase 2/3 trial, now advancing to phase 3, GSK stated that the trial met its pre-specified expansion criteria per protocol.

"These trials support the ambition for dostarlimab to become the backbone of our ongoing immuno-oncology-based research and development programme when used alone and in combination with standard of care and future novel cancer therapies, particularly in patients with currently limited treatment options," said Hesham Abdullah, Senior Vice President & Global Head of GSK's Oncology Development arm.

[paul planet earth] 08/10/2022 16:40

'Forced Recession'..whats that all about!

[pol123] 08/10/2022 12:16

Forced recession in the US, works well for big Pharma for obvious reasons, strong dollar, resilient earnings I could go on. Makes GSK one of the best plays around IMO. I have recently stated we will be back to £15+ over the next 6 months. One caveat being Russia going nuclear

[tradermichael] 07/10/2022 11:49

Its entirely probable, given third quarter 2022 results on Wednesday 2 November.

These are expected to show a strong performance, especially with the strong dollar vs the weak pound.

[tuftymatt] 07/10/2022 10:53

That's a difficult one net as wider market conditions could keep it lower.
I think the company specific "bad news" has to be priced in so hopefully it slowly climbs back up. It would only need circa 3% a week from now to get to 1450 so it's possible.

[netcurtains] 07/10/2022 10:47

Do you think this might break through 1450 by November?

[paul planet earth] 06/10/2022 22:09

Try pressing filter button then tw@t!

[cumnor] 06/10/2022 20:28

The guy is a penniless dolt-spends his jobless days on ADVFN trolling various boards. Filtered the loser ages ago.

[paul planet earth] 06/10/2022 19:39

Jeepers TM nobody knows the full extent of the Zantac litigation and which companies will get hit with legal costs. As for cashflow 9 billion shares 1.8p or 3.6p assuming 100% payout, 50% payout yield just 1.8p per share that is terrible!!!

[rikky72] 06/10/2022 11:10

PPE is just a troll and not worth the effort indulging..

[tradermichael] 06/10/2022 10:22

GSK dividends in my accounts this morning (thx to AJ Bell)

[tradermichael] 06/10/2022 08:56

PPE, I think you are overreacting. Haleon has said it had rejected indemnification requests from GSK and Pfizer “on the basis that the scope of the indemnities set out in the joint venture agreement only covers their consumer healthcare businesses as conducted when the JV was formed in 2018”.

It added: “At that time, neither GSK nor Pfizer marketed [over the counter] Zantac in the US or Canada.”

Litigation surrounding Zantac, which was previously marketed by GSK and Pfizer is a distraction, but Haleon itself never marketed this product and significant financial costs are not anticipated, other than those of defending the litigation, being incurred by Haleon as a result.

And on cash flow, the group expects continued growth in the second half of the year, albeit not at such a strong pace. Cash flow was especially strong, with the group delivering free cash flow of over £550m in the half-year, compared to £364m at the 2021 half-year stage.
With strong cash flows, Haleon should rapidly deleverage, which will help to drive financial returns higher, over and above the growth from the brands portfolio. Haleon should have excellent dividend growth potential over the longer term as a result.

[paul planet earth] 06/10/2022 08:21

Doubt it GSK and Pfizer will start dumping come November afterall you've got a multi billion dollar Zantac law suite to fund. Why hold Haleon shares that generate f@@kall cash flow!

[alibizzle] 06/10/2022 08:01

Feel free to dump your shares Paul , wiser to keep them though

[paul planet earth] 06/10/2022 07:48

Haleon H2 results EPS 9p a share so 3p to 4.5p dividend payout to GSK investors..better dumping those shares at 270p not even a 2% share holder yield!..Most of their free cash flow used up servicing £8 billion debt ffs and that's at just 2.8% f@@k knows how they will cope as interest rates rise and find debt reduction is harder to achieve, higher inflation, rising cost base, consumers cutting spending and switching to generic cheaper rivals brands!

[tradermichael] 06/10/2022 07:31

PPE: In its H1 earnings report, Haleon expected the initial dividend to be at the lower end of a 30%-50% pay-out ratio, subject to board approval.

[tradermichael] 05/10/2022 08:53

Glaxo Wellcome (GW) and SmithKline Beecham (SB) joined forces at the end of 2000. The £114 billion merger created a giant with an estimated global market share of 7% of the world pharmaceutical market.

In over 20 years since then, how much has the company added value to the business?

[paul planet earth] 04/10/2022 19:20

Thats alot of shares to dump especially as Halitosis told both Pfizer and GSK to get stuffed regarding the Zantac indemnities.

[tradermichael] 04/10/2022 09:07

Still a lot of dust in the air until after the options to sell in November following the 'lock-up' period ....
(Pfizer, 32%, GSK 6%)

[paul planet earth] 04/10/2022 08:38

Any views on the Halitosis IPO sell off..was it a good or bad move by the GSK board in light of Unlevers original offer now the dust has settled?